Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04675333
Title ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | GBR | ESP | BEL | AUS


No variant requirements are available.